Sands Capital, an Arlington, VA-based investor in innovative businesses globally, closed its third life sciences fund, Sands Capital Life Sciences Pulse Fund III, at $555M.
Pulse III will continue the firm’s strategy of investing in private therapeutics, diagnostics, medical devices, and life sciences tools businesses.
The close increases total Pulse strategy capital commitments to $1.3 Billion, including Sands Capital Life Sciences Pulse Fund and Sands Capital Life Sciences Pulse Fund II.
Founded in 1992, Sands Capital invests in businesses globally. Through an integrated investment platform spanning venture capital, private growth equity and public growth equity, the firm provides growth capital solutions to institutions and fund sponsors in more than 40 countries.
As of March 31, 2024, Sands Capital managed over $54 Billion in public and private equity investments including more than $5 Billion in life sciences and health care companies globally across all strategies.
The firm has offices in the Washington, D.C. area, San Francisco, London, and Singapore. Led by Stephen Zachary, Managing Partner, the Pulse investment team includes senior professionals led by founders, operators, PhDs, and experienced investors with the ability to leverage the resources and capabilities of the entire firm to execute its strategy.
